MedTrace Logo

Assessment of Efficacy & Safety for a New Wound Dressing Urgo 310 3166 in the Local Treatment of VLU or Mixed Leg Ulcers

NCT02583958 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-10-22

No results posted yet for this study

Summary

Assessment of efficacy and safety for a new wound dressing URGO 310 3166 in the local treatment of venous or mixed leg ulcers: a European, randomised clinical trial.

Conditions

  • Leg Ulcers

Interventions

DEVICE

Urgo 3103166

URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).

DEVICE

Aquacel Extra

Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.

Sponsors & Collaborators

  • Laboratoires URGO

    lead INDUSTRY

Principal Investigators

  • Sylvie Meaume, MD · Hospital Rothschild - Paris - France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-01-31
Completion
2017-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02583958 on ClinicalTrials.gov